ShangPharma pumps $60m into Qidong biologics plant for international clients
China’s ShangPharma is building a $60m (€53m) single-use biologics manufacturing plant in Qidong, to be operated by its CMO subsidiary.
News & Analysis on the Clinical Development and Manufacture of Large Molecule Drugs